Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 104, Issue 1, 2010, Pages 1-2

  Musa, Ahmed Mudawi ^a   Noazin, Sassan ^b   Khalil, E A G ^a   Modabber, Farrokh ^a,c,d  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

Immunochemotherapy; Immunocompromised; Immunostimulation; Immunotherapy; Leishmaniasis; Therapy

Indexed keywords

AMPHOTERICIN B; ANTIMONY; ANTIMONY DERIVATIVE; B7 ANTIGEN; BCG VACCINE; CD86 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INACTIVATED VACCINE; LEISHMANIA VACCINE; MAYRINK VACCINE; MILTEFOSINE; PAROMOMYCIN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ARTHRALGIA; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION PREVENTION; INJECTION SITE PAIN; LEISHMANIA; LEISHMANIASIS; LOW DRUG DOSE; MONOTHERAPY; MUCOSAL LEISHMANIASIS; MYALGIA; NAUSEA; NONHUMAN; PARASITE CONTROL; REVIEW; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; TH2 CELL; UPREGULATION; VACCINATION; VACCINE PRODUCTION; VISCERAL LEISHMANIASIS; VOMITING;

ANIMALS; ANTIPARASITIC AGENTS; HUMANS; IMMUNIZATION; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS;

EID: 70649087040     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2009.07.026     Document Type: Review

References (6)

1. Convit J., Ulrich M., Zerpa O., Borges R., Aranzazu N., Valera M., et al. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 97 (2003) 469-472
2. Machado-Pinto J., Pinto J., da Costa C.A., Genaro O., Marques M.J., Modabber F., et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 41 (2002) 73-78
3. Musa A.M., Khalil E.A.G., Mahgoub F.A., Elgawi S.H., Modabber F., Elkadaru A.E., et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg 102 (2008) 58-63
4. Badaro R., Lobo I., Munos A., Netto E.M., Modabber F., Campos-Neto A., et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 194 (2006) 1151-1159
5. Badaro R., and Johnson Jr. W.D. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J Infect Dis 167 Suppl 1 (1993) S13-S17
6. Ismail A., Khalil E.A.G., Musa A.M., Elhassan I.M., Ibrahim M.E., Theander T.G., et al. The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role?. Med Hypotheses 6 (2006) 993-999